How to Cite
Abstract
The study of the pathogenetic features of malignant tumors associated with metabolic syndrome (MS) is relevant because of high incidence of these tumors. Investigations of the mechanisms of involvement of MS in the pathogenesis of cancer reasonably supplemented by the study of transcription and growth factors associated with energy imbalance of the cell and involved in proliferation, apoptosis, angiogenesis, cell motility and inflammation. More research is needed to identify the most promising molecular targets for therapy of malignant tumors associated with MS with a view to increasing the survival and quality of life of these patients.References
Берштейн, Л.М. Онкоэндокринология. Традиции, современность и перспективы / Л.М. Берштейн. - СПб.: Наука, 2004. - 343 с.
Берштейн Л.М., Евтушенко Т.П., Цырлина Е.В. и др. Сравнительное изучение пяти- и десятилетних результатов метаболической реабилитации онкологических больных. В кн.: Нейроэндокринная система, метаболизм, иммунитет и рак (ред. К.П. Хансон, В.М. Дильман). - СПб., 1992. - С. 102-112.
Биологические маркеры опухолей: фундаментальные и клинические исследования / Под ред. Н.Е. Кушлинского, М.А. Красильникова. - М.: Издательство РАМН, 2017. - 632 с.
Бочкарева Н.В., Коломиец Л.А., Кондакова И.В. Сочетание гиперплазии и рака эндометрия с миомой матки: роль половых гормонов, их рецепторов и ферментов метаболизма эстрогенов // Вопросы онкологии. - 2005. - Т 51. - № 4. - С. 427-433.
Коломиец Л.А., Бочкарева Н.В., Чернышева А.Л. Рак эндометрия и метаболический синдром. - Томск: Типография «Иван Федоров», 2010. - 228 с.
Кручинина М.В., Курилович С.А., Громов А.А. и др. Кардиометаболические факторы и колоректальный рак // Атеросклероз. - 2016. - Т. 12. - № 1. - C. 46-60.
Любота Р.В. Применение метформина в лечении рака молочной железы у больных с метаболическим синдромом // Опухоли женской репродуктивной системы. - 2015. - № 4. - C. 18-24.
Alshaker H., Sacco K., Alfraidi A. et al. Leptin signalling, obesity and prostate cancer: molecular and clinical perspective on the old dilemma // Oncotarget. - 2015. - Vol. 6. - № 34. - P. 35556-35563.
Azhar S. Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease // Future Cardiol. - 2010. - Vol. 6. № 5. - P. 657-691.
Berstein L.M. Modern approach to metabolic rehabilitation of cancer patients: biguanides (phenformin and metformin) and beyond // Future Oncology. - Vol. 6. - № 8. - P. 1313-1323.
Catalano S., Mauro L., Marsico S. et al. Leptin induces, via ERK1/ERK2 signal, functional activation of estrogen receptor alpha in MCF-7 cells // J. Biol. Chem. - 2004. - Vol. 279. - № 19. - P. 19908-19915.
Chia P.-P., Fan S.-H., Say Y-H. Screening of peroxisome proliferator-activated receptors (PPARs) a, у and ß gene polymorphisms for obesity and metabolic syndrome association in the multi-ethnic Malaysian population // Ethn. Dis. - 2015. - Vol. 25. - № 4. - P. 383-390.
Cowey S., Hardy R.W. The metabolic syndrome a high-risk state for cancer? // Am. J. of Pathology. - 2006. - Vol. 169. - № 5. - P. 1505-1522.
Dekker M.J., Su Q., Baker C. et al. Fructose: a highly lipogenic nutrient implicated in insulin resistance, hepatic steatosis, and the metabolic syndrome // Am. J. Physiol. Endocrinol. Metab. - 2010. - Vol. 299. - № 5. - E685-694.
Ding J., Li C., Tang J. et al. Higher expression of proteins in IGF/IR axes in colorectal cancer is associated with type 2 diabetes mellitus // Pathol. Oncol. Res. - 2016. - Vol.22. - № 4. - P. 773-779.
Esposito K., Chiodini P., Colao A. et al. Metabolic syndrome and risk of cancer: a system review and meta-analysis // Diabetes Care. - 2012. - Vol. 35. - P. 2402-2411.
Gao J., Tian J., Lv Y. et al. Leptin induces functional activation of cyclooxygenase-2 through JAK2/STAT3, MAPK/ERK, and PI3K/AKT pathways in human endometrial cancer cells // Cancer Sci. - 2009. - Vol. 100. - № 3. - P. 389-395.
Guigas B., Viollet B. Targeting AMPK: from ancient drugs to new small-molecule activators // EXS. - 2016. - Vol. 107. - P. 327-350.
Grisouard J., Dembinski K., Mayer D. et al. AMP-activated protein kinase in adipocytes to modulate obesity-related adipokine production associated with insulin resistance and breast cancer cell proliferation // Diabetol Metab Syndr. - 2011. - Vol. 20. - P. 16. - DOI: 10.1186/1758-5996-3-16
Karnati H.K., Panigrahi M.K., Li Y. et al. Adiponectin as a potential therapeutic target for prostate cancer // Curr. Pharm. Des. - 2017. - DOI: 10.2174/1381612823666170208123553
Kato S., Abarzua-Catalan L., Trigo C. et al. Leptin stimulates migration and invasion and maintains cancer stemlike properties in ovarian cancer cells: an explanation for poor outcomes in obese women // Oncotarget. - 2015. - Vol. 6. - № 25. - P. 21100-21119.
Kim J., Yang G., Kim Y. et al. AMPK activators: mechanisms of action and physiological activities // Exp. Mol. Med. - 2016. - Vol. 48. - № 4. - e224.
Kim A.Y. Lee Y.S., Kim K.H. et al. Adiponectin represses colon cancer cell proliferation via AdipoR1- and -R2-mediated AMPK activation // Mol. Endocrinol. - 2010. - Vol. 24. - № 7. - P. 1441-1452.
Ko S., Yoon S.J., Kim D. et al. Metabolic risk profile and cancer in Korean men and women // J. Prev. Med. Public Health. - 2016. - Vol. 49. - № 3. - P. 143-152.
Koda M., Sulkowska M., Wincewicz A. et al. Expression of leptin, leptin receptor, and hypoxia-inducible factor 1 alpha in human endometrial cancer // Ann N Y Acad Sci.-2007. - Vol. 1095. - P. 90-98.
Lagana A.S., Vitale S.G., Nigro A. et al. Pleiotropic action of peroxisome proliferator-activated receptors (PPARs) in dysregulated metabolic homeostasis, inflammation and cancer: current evidence and future perspectives // International J. of Molecular Science. - 2016. - Vol. 17. - № 7. - pii: E999. - DOI: 10.3390/ijms17070999
Lai L., Wang M., Martin O.J. et al. A role for peroxisome proliferator-activated receptor у coactivator 1 (PGC-1) in the regulation of cardiac mitochondrial phospholipid biosynthesis // J. Biol. Chem. - 2014. - Vol. 289. - № 4. - P. 2250-2259.
Li L., Zhao Z., Xia J. et al. A Long-term high-fat/high-su-crose diet promotes kidney lipid deposition and causes apoptosis and glomerular hypertrophy in Bama minipigs // PLoS One. - 2015. - Vol. 10. - № 11. - e0142884. - DOI: 10.1371/journal.pone.0142884
Liu N., Zhao J., Wang J. et al. Farnesoid X receptor ligand CDCA suppresses human prostate cancer cells growth by inhibiting lipid metabolism via targeting sterol response element binding protein 1 // Am. J. Transl. Res. - 2016. - Vol. 8. - № 11. - P. 5118-5124.
Liu C.Y., Su J.C., Huang T.T. et al. Sorafenib analogue SC-60 induces apoptosis through the SHP-1/STAT3 pathway and enhances docetaxel cytotoxicity in triple-negative breast cancer cells // Mol. Oncol. - 2017. - Vol.11. - № 3. - P. 266-279.
Malih S, Najafi R. AdipoRon: a possible drug for colorectal cancer prevention? // Tumour Biol. - 2015. - Vol. 36. - № 9. - P. 6673-6675.
Mauro L., Pellegrino M., De Amicis F., et. al. Evidence that estrogen receptor a interferes with adiponectin effects on breast cancer cell growth // Cell Cycle. - 2015. - Vol. 13. - P. 553-554.
McCormack D., Schneider J., McDonald D., McFadden D. The antiproliferative effects of pterostilbene on breast cancer in vitro are via inhibition of constitutive and leptin-induced Janus kinase/signal transducer and activator of transcription activation // Am. J. Surg. - 2011. - Vol. 202. - № 5. - P. 541-544.
Merino V.F., Cho S., Liang X. et al. Inhibitors of STAT3, ß-catenin, and IGF-1R sensitize mouse PIK3CA-mu-tant breast cancer to PI3K inhibitors // Mol. Oncol. - 2017. - DOI: 10.1002/1878-0261.12053
Moreno-Arriola E., El Hafidi M., Ortega-Cuéllar D. et al. AMP-activated protein kinase regulates oxidative metabolism in Caenorhabditis elegans through the NHR-49 and MDT-15 transcriptional regulators // PLoS One. - 2016. - Vol.11. - № 1. - e0148089. - DOI: 10.1371/journal.pone.0148089
Nambiar D.K., Deep G., Singh R.P. et al. Silibinin inhibits aberrant lipid metabolism, proliferation and emergence of an-drogen-independence in prostate cancer cells via primarily targeting the sterol response element binding protein 1 // Oncotarget. - 2014. - Vol. 5. - № 20. - P. 10017-10033.
Nejati-Koshki K., Akbarzadeh A., Pourhasan-Moghaddam M. et al. Inhibition of leptin and leptin receptor gene expression by silibinin-curcumin combination // Asian Pac. J. Cancer Prev. - 2014. - Vol. 14. - № 11. - P. 6595-6599.
Ogunwobi O.O., Beales I.L. The anti-apoptotic and growth stimulatory action of leptin in human colon cancer cells involves activation of JNK mitogen activated protein kinase JAK2 and PI3 kinase/Akt // Int. J. Colorectal Dis. - 2007. - Vol. 22. - № 4. - P. 401-409.
Odate S., Veschi V., Yan S. et al. Inhibition of STAT3 with the generation 2.5 antisense oligonucleotide, AZD9150, decreases neuroblastoma tumorigenicity and increases chemosensitivity // Сiiп. Cancer Res. - 2017. - Vol. 23. - № 7. - P. 1771-1784.
Osaki Y. Taniguchi S., Tahara A. et al. Metabolic syndrome and incidence of liver and breast cancers in Japan // Cancer Epidemiol. - 2012. - Vol. 36. - № 2. - P. 141-147.
Rosato V., Zucchetto A., Bosetti C. et al. Metabolic syndrome and endometrial cancer risk // Annals of Oncology. - 2011. - Vol. 22. - P. 884-889.
Ruiz R., Jideonwo V., Ahn M. et al. Sterol regulatory element-binding protein-1 (SREBP-1) is required to regulate glycogen synthesis and gluconeogenic gene expression in mouse liver //J. Biol. Chem. - 2014. - Vol. 289. - № 9. - P. 5510-5517.
Saengboonmee C., Seubwai W., Cha'on U. et al. Metformin exerts antiproliferative and anti-metastatic effects against cholangiocarcinoma cells by targeting STAT3 and NF-kB //Anticancer Res. - 2017. - Vol. 37. - № 1. - P. 115-123.
Samani A.A., Yakar S., Leroith D. et al. The role of the IGF system in cancer growth and metastasis: overview and recent insight //Endocrine Reviews. - 2007. - Vol. 28. - № 1. - P. 20-47.
Scheithauer T.P., Dallinga-Thie G.M., de Vos W.M. et al. Causality of small and large intestinal microbiota in weight regulation and insulin resistance // Mol. Metab. - 2016. - Vol. 5. - № 9. - P.759-770.
Sharma D., Saxena N.K., Vertino P.M., Anania F.A. Leptin promotes the proliferative response and invasiveness in human endometrial cancer cells by activating multiple signal-transduction pathways // Endocr. Relat. Cancer. - 2006. - Vol. 13. - № 2. - P. 629-640.
Shebl F.M., Andreotti G., Meyer T.E. et al. Metabolic syndrome and insulin resistance in relation to biliary tract cancer and stone risks: a population-based study in Shanghai, China // Br. J. Cancer. - 2011. - Vol. 105. - № 9. - P. 1424-1429.
Spirina L.V., Bochkareva N.V., Kondakova I.V. et al. Regulation of insulin-like growth NF-kB proteasome system in endometrial cancer // Molecular Biology. - 2012. - Vol. 46. - № 3. - P. 407-413.
Spirina L.V., Yunusova N.V., Kondakova I.V. et al. Association of growth factors, HIF-1 and NF-kB expression with proteasome in endometrial cancer // Molecular Biology Reports. - 2012. - Vol. 39. - № 9. - P. 8655-8662.
Sugiyama M., Takahashi H., Hosono K. et al. Adiponectin inhibits colorectal cancer cell growth through the AMPK/ mTOR pathway // Int. J. Oncol. - 2009. - Vol. 34. - № 2. - P. 339-344.
Tae C.H., Kim S.E., Jung S.A., et al. Involvement of adiponectin in early stage of colorectal carcinogenesis // BMC Cancer.-2014, 14, 811. DOI: 10.1186/1471-2407-14-811
Wen S., Niu Y., Lee S.O. et al. Targeting fatty acid synthase with ASC-J9 suppresses proliferation and invasion of prostate cancer cells // Mol Carcinog. - 2016. - Vol. 55. - № 12. - P. 2278-2290.
Wu X., Yan Q., Zhang Z. et al. Acrp30 inhibits leptin-induced metastasis by downregulating the JAK/STAT3 pathway via AMPK activation in aggressive SPEC-2 endometrial cancer cells // Oncol. Rep. - 2012. - Vol. 27. - № 5. - P. 1488-1496.
Wu C.Y., Yang Y.H., Lin Y.Y. et al. Anti-cancer effect of danshen and dihydroisotanshinone I on prostate cancer: targeting the crosstalk between macrophages and cancer cells via inhibition of the STAT3/CCL2 signaling pathway // Oncotarget. - 2017. - DOI: 10.18632/oncotarget.14958
Yunusova N.V., Spirina L.V., Kondakova I.V. et al. Relationship between the expression levels of PAPP-A metalloproteinase and growth and transcriptional factors in endometrial cancer // Biology Bulletin. - 2013. - Vol. 40. - № 3. - P. 253-259.
Yunusova N.V., Spirina L.V., Frolova A.E. et al. Association of IGFBP-6 expression with metabolic syndrome and adipo-nectin and IGF-IR receptor levels in colorectal cancer // Asian Pac. J. of Cancer Prev. - 2016. - Vol. 17. - № 8. - P. 3961-3967.
Yunusova N.V., Villert A.B., Spirina L.V. et al. Insulin-like growth factors and their binding proteins in tumor and ascites of ovarian cancer patients: association with response to neoadjuvant chemotherapy //Asian Pac. J. Cancer Prev. - 2016. - Vol. 17. - № 12. - P. 6215-6219.
Zhao Y.-y., Guo L., Zhao X-y. et al. Transcriptional activation of insulin-like growth factor binding protein 6 by 17ß-estradiuol in SaOS-2 cells // Exp. Mol. Med. - 2009. - Vol. 41. - № 7. - P. 478-486.
Zhang H., Yee D. Is the type I insulin-like growth factor receptor a therapeutic target in endometrial cancer? // Clinical Cancer Research. - 2006. - Vol. 12. - P. 6323-6325.
Zhou J-R., Blackburn G.L., Walker W.A. Symposium introduction: metabolic syndrome and the onset of cancer // Am. J. Clin. Nutr. - 2007. - Vol. 86. - № 3. - P. 817S-819S.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2017